# Phase 3 tuberculosis trials recruiting: 26 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials in phase 3 for tuberculosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 tuberculosis trials: 26 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/tuberculosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 26
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947056 | A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose... | Tuberculosis Research Centre, India | Phase 3 | Recruiting | Tuberculosis, Pulmonary, Drug Sensitive | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947056) |
| June 30, 2026 | NCT07675954 | A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis | Seoul National University Hospital | Phase 3 | Not yet recruiting | Rifampicin-Resistant Tuberculosis | 294 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07675954) |
| March 20, 2026 | NCT07486024 | Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR) | Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | MDR-TB, Tuberculosis Multi Drug Resistant Active, Antibiotic Resistance, Mycobacterium Tuberculosis | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486024) |
| January 12, 2026 | NCT07332325 | STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis | University of Virginia | Phase 3 | Not yet recruiting | Sepsis, Tuberculosis | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07332325) |
| December 8, 2025 | NCT07268664 | Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort | Beijing Chest Hospital | Phase 3 | Not yet recruiting | Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis, Drug-resistant Tuberculosis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268664) |
| October 7, 2025 | NCT07209761 | A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Recruiting | Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis | 532 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07209761) |
| September 9, 2025 | NCT07163143 | Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding... | University College, London | Phase 3 | Recruiting | Tuberculosis (TB) | 784 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07163143) |
| September 3, 2025 | NCT07152639 | Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years... | Chengdu CoenBiotech Co., Ltd | Phase 3 | Recruiting | Tuberculosis | 1,784 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07152639) |
| August 22, 2025 | NCT07136987 | A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery | Open Source Pharma Foundation | Phase 3 | Not yet recruiting | Tuberculosis | 1,104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136987) |
| August 12, 2025 | NCT07118696 | Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease | Hamilton Health Sciences Corporation | Phase 3 | Not yet recruiting | Pulmonary TB | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07118696) |
| July 22, 2025 | NCT07076225 | Ultra-Short Regimen for Elderly DS-TB | Shenzhen Third People's Hospital | Phase 3 | Not yet recruiting | Pulmonary Tuberculosis | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07076225) |
| April 1, 2025 | NCT06905522 | A PAN-USR TB Multi-Center Trial | Shenzhen Third People's Hospital | Phase 3 | Recruiting | Pulmonary Tuberculosis | 610 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06905522) |
| December 11, 2024 | NCT06727864 | Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial | Kaohsiung Veterans General Hospital. | Phase 3 | Recruiting | Pulmonary Tuberculosis | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06727864) |
| July 29, 2024 | NCT06526039 | A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB | Taipei Medical University WanFang Hospital | Phase 3 | Not yet recruiting | Tuberculosis, Pulmonary | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06526039) |
| July 11, 2024 | NCT06497465 | Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment | Johns Hopkins University | Phase 3 | Recruiting | Tuberculosis, HIV | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06497465) |
| February 12, 2024 | NCT06253715 | Shortened Regimen for Drug-susceptible TB in Children | Johns Hopkins University | Phase 3 | Recruiting | Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis | 860 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06253715) |
| September 28, 2023 | NCT06057519 | Pragmatic Optimized Rifampicin Trial | Radboud University Medical Center | Phase 3 | Recruiting | Tuberculosis, Pulmonary | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06057519) |
| September 1, 2023 | NCT06022146 | A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts... | Huashan Hospital | Phase 3 | Recruiting | Tuberculosis, Latent Tuberculosis | 3,520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06022146) |
| June 23, 2023 | NCT05917340 | Intensified Short Course Regimen for TBM in Adults | Indian Council of Medical Research | Phase 3 | Not yet recruiting | Tuberculous Meningitis | 372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05917340) |
| April 24, 2023 | NCT05824871 | A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients | Shanghai Jiatan Pharmatech Co., Ltd | Phase 3 | Recruiting | Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB) | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05824871) |
| July 26, 2022 | NCT05473520 | Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis | National University Hospital, Singapore | Phase 3 | Recruiting | Tuberculosis, Acute Coronary Syndrome, Pulmonary Hypertension (Diagnosis) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05473520) |
| October 18, 2021 | NCT05081401 | Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB) | Huashan Hospital | Phase 3 | Recruiting | Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB | 1,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05081401) |
| July 23, 2021 | NCT04975178 | Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa | Biofabri, S.L | Phase 3 | Recruiting | Tuberculosis | 7,120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04975178) |
| July 24, 2020 | NCT04485156 | Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3) | Seoul National University Hospital | Phase 3 | Not yet recruiting | Tuberculosis, Pulmonary | 926 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04485156) |
| February 7, 2020 | NCT04260477 | Novel Triple-dose Tuberculosis Retreatment Regimen | Institute of Tropical Medicine, Belgium | Phase 3 | Recruiting | Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis, Resistance to Tuberculostatic Drugs | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04260477) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Shenzhen Third People's Hospital | 2 |
| Huashan Hospital | 2 |
| Seoul National University Hospital | 2 |
| Johns Hopkins University | 2 |
| [Otsuka Pharmaceutical Development & Commercialization, Inc.](https://specstream.ai/data/clinical-trials/company/otsuka-pharmaceutical-development-and-commercialization-inc) | 1 |
| Biofabri, S.L | 1 |
| Hamilton Health Sciences Corporation | 1 |
| National University Hospital, Singapore | 1 |
| Open Source Pharma Foundation | 1 |
| Chengdu CoenBiotech Co., Ltd | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Institute of Tropical Medicine, Belgium | 1 |
| University College, London | 1 |
| ANRS, Emerging Infectious Diseases | 1 |
| Kaohsiung Veterans General Hospital. | 1 |
| Indian Council of Medical Research | 1 |
| University of Virginia | 1 |
| Taipei Medical University WanFang Hospital | 1 |
| Radboud University Medical Center | 1 |
| Shanghai Jiatan Pharmatech Co., Ltd | 1 |
| Tuberculosis Research Centre, India | 1 |
| Beijing Chest Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 7 |
| South Africa | 6 |
| India | 4 |
| Uganda | 3 |
| Indonesia | 2 |
| South Korea | 2 |
| Zimbabwe | 2 |
| Georgia | 1 |
| Japan | 1 |
| Moldova | 1 |
| Peru | 1 |
| Philippines | 1 |
| Malaysia | 1 |
| Singapore | 1 |
| France | 1 |
| Niger | 1 |
| Pakistan | 1 |
| Brazil | 1 |
| Côte d’Ivoire | 1 |
| Madagascar | 1 |
| Taiwan | 1 |
| Tanzania | 1 |
| Mozambique | 1 |
| Zambia | 1 |
| Italy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Orthotics providers in the United States](https://specstream.ai/data/businesses/orthotics-providers/united-states)
- [Tapas bars in the United States](https://specstream.ai/data/businesses/tapas-bars/united-states)
- [Bags luggage companies in the United States](https://specstream.ai/data/businesses/bags-luggage-companies/united-states)
- [Employment agencies in the United States](https://specstream.ai/data/businesses/employment-agencies/united-states)
- [Laser cutting companies in the United States](https://specstream.ai/data/businesses/laser-cutting-companies/united-states)
- [Rail freight companies in the United States](https://specstream.ai/data/businesses/rail-freight-companies/united-states)
